R&D channel feed – Endpoints News

R&D channel feed

Sanofi, Regeneron prep another FDA submission for Dupixent, this time for a rare skin condition

8 months ago

Novo's oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

8 months ago

GSK discontinues herpes therapeutic vaccine after Phase 2 disappointment

8 months ago

Sanofi, Regeneron to refile Dupixent for skin condition after new study win

8 months ago

BridgeBio ends development of gene therapy for adrenal gland disorder

8 months ago

Adicet follows other cell therapy biotechs in autoimmune pivot

8 months ago

Lilly's weekly insulin hits primary endpoints in two more late-stage diabetes studies

8 months ago

Roche's dual GLP-1/GIP results show promising weight loss, but also high rates of vomiting

8 months ago

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

8 months ago

Updated: Viridian reveals first Phase 3 eye disease data in bid to compete with Tepezza

8 months ago

Centessa to take narcolepsy drug into Phase 2 after no sign of side effects that doomed earlier competitor

8 months ago

Bayer's treatment for menopause symptoms hits primary endpoints in third late-stage trial

8 months ago

#WCLC24 roundup: ArriVent thinks its drug can fill Tagrisso's gaps; Boehringer, Bayer's data in HER2-mutated lung cancer

8 months ago

GSK says long-acting asthma hopeful significantly cut attacks

8 months ago

AstraZeneca, Gilead detail TROP2 ADC data in lung cancer as they search for new ways forward

8 months ago

Zealand’s GLP-1/GLP-2 drug bounces back with new Phase 1b data

8 months ago

#ESMO24 roundup: New data on Amgen’s PRMT5 inhibitor seem lackluster, and Jazz’s HER2 antibody

8 months ago

AstraZeneca's monoclonal antibody misses primary endpoint in mid-stage trial in COPD

8 months ago

Bicycle Therapeutics makes an early case for its Padcev competitor: #ESMO24

8 months ago

Merck, Daiichi Sankyo detail Phase 2 ADC results in small cell lung cancer, bispecific combo strategy

8 months ago

Relay Therapeutics reports positive PFS data for its PI3Kα inhibitor combo in breast cancer

8 months ago

Terns’ oral GLP-1 passes Phase 1 test with promising weight loss after one month

8 months ago

Summit's Phase 3 data back up biotech's boasts of beating Keytruda in lung cancer

8 months ago

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

8 months ago

First page Previous page 26 27 282930 31 32 Next page Last page